Evidence map›Paper›PMID 40041687›Full record

ArticleHealth psychology research2025

Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns.

Patrick Brown, Alexa Ryder, Christopher Robinson, Kayla Valenti, Katie Phung, Jamal Hasoon

Abstract read
In one paragraph

Article in Health psychology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Molecular mechanism of allosteric modulation of opioid receptors.Signal transduction and targeted therapy · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Mixed-mechanism analgesics for mixed pain.Frontiers in medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrick BrownDepartment of Neurology University of Texas Health Science Center at Houston, Houston, TX, USA.
Alexa RyderDepartment of Physical Medicine and Rehabilitation University of Texas Health Science Center at Houston, Houston, TX, USA.
Christopher RobinsonDepartment of Anesthesiology, Perioperative, and Pain Medicine Brigham and Women's Hospital, Boston, MA, USA.
Kayla ValentiDrexel University College of Medicine, Philadelphia, PA, USA.
Katie PhungDepartment of Anesthesiology University of Texas Health Science Center at Houston, Houston, Texas, USA.
Jamal HasoonDepartment of Anesthesiology University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-8227-1864

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose of Review: Methadone is a synthetic opioid extensively used in opioid use disorder management but is gaining recognition for its unique pharmacological properties that make it a viable alternative for chronic pain management. This review aims to explore methadone's pharmacokinetics, pharmacodynamics, efficacy, and safety profile to assess its potential role in managing chronic pain conditions. Recent Findings: Methadone's dual action as a mu-opioid receptor agonist and NMDA receptor antagonist positions it as an effective option for managing both nociceptive and neuropathic pain. It has shown promising results in cancer pain management, refractory pain, and opioid rotation strategies. Despite its therapeutic advantages, concerns regarding its narrow therapeutic window, variable pharmacokinetics, QT interval prolongation, and risk of respiratory depression highlight the need for careful patient selection and monitoring. New evidence also sheds light on its affordability and efficacy in low-resource settings, as well as its controversial role in mitigating opioid-induced hyperalgesia. Summary: Methadone offers a unique therapeutic option in chronic pain management due to its multifaceted pharmacological properties. While it provides significant benefits for patients with complex pain syndromes, clinicians must exercise caution due to its safety concerns and variability in individual metabolism. A personalized approach, combined with rigorous monitoring, is essential to optimize its benefits while minimizing risks. Further research is needed to better define its role in chronic pain treatment and address unresolved safety concerns.

Indexed as

Chronic PainMethadoneNMDA antagonist.OpioidsPharmacodynamicsPharmacokineticsSafety Profile

Identifiers

PMID40041687
PMCPMC11879063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.